FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2183688881> ?p ?o ?g. }

• W2183688881 abstract "Introduction: The normalization of cellular glucose assimilation is the basic aim of therapy in diabetes mellitus. This process should be accompanied by a proportional increase of the cellular glucose transport (CGT). The level of CGT should react to therapy typically recommended in Type 2 diabetes mellitus (T2DM), composed of diet and sulfonylurea. In order to explore this clinically significant hypothesis, a clinical-experimental study was undertaken. Its aim was to determine the clinical pharmacotherapeutic significance of CGT measurements. Material and methods: CGT testing was performed on peripheral blood lymphocytes. CGT was assessed with 2-[ 3 H(G)] glucose: before, and after the addition of sulfonylurea or sulfonylurea plus insulin to the incubation medium. Tests were performed at baseline in 28 persons with newly diagnosed, “therapeutically naive” T2DM and in 20 control subjects. In diabetic patients the tests for CGT were repeated after 3 months of routine diet and sulfonylurea therapy. In addition, the level of GLUT4 expression was assessed by flow cytometry before and after this therapy. Results: Before treatment, CGT was significantly decreased in all subjects with T2DM. Incubated in-vitro cells responded directly to the addition of sulfonylurea with a moderate increase of CGT. This response was augmented by the addition of insulin to sulfonylurea in the incubation medium. The monitored three-month routine, controlled therapy with diet and sulfonylurea resulted in a significant increase of CGT process in all types of incubation tests. Conclusions: The basal and reactive CGT is significantly decreased in lymphocytes of persons with T2DM before the introduction of therapy. Effective therapy with diet and sulfonylurea normalizes both types of CGT — basal and reactive. It is related to the near normalization of GLUT4 expression in the studied cells. This phenomenon may be used as a new marker for diabetes mellitus pharmacotherapy. (Pol J Endocrinol 2010; 61 (1): 75–81)" @default.
• W2183688881 created "2016-06-24" @default.
• W2183688881 creator A5079477497 @default.
• W2183688881 date "2010-01-01" @default.
• W2183688881 modified "2023-09-27" @default.
• W2183688881 title "Does cellular glucose transport respond to a controlled diet and sulfonylurea therapy in type 2 diabetes mellitus? Czy leczenie dietą i pochodną sulfonylomocznika wpływa na dokomórkowy transport glukozy u chorych na cukrzycę typu 2?" @default.
• W2183688881 cites W1725854756 @default.
• W2183688881 cites W1966526637 @default.
• W2183688881 cites W1973728940 @default.
• W2183688881 cites W1974519753 @default.
• W2183688881 cites W1980903176 @default.
• W2183688881 cites W2011419421 @default.
• W2183688881 cites W2012079492 @default.
• W2183688881 cites W2034293014 @default.
• W2183688881 cites W2038823822 @default.
• W2183688881 cites W2064103928 @default.
• W2183688881 cites W2069231976 @default.
• W2183688881 cites W2080984264 @default.
• W2183688881 cites W2082983470 @default.
• W2183688881 cites W2340078041 @default.
• W2183688881 cites W48648283 @default.
• W2183688881 hasPublicationYear "2010" @default.
• W2183688881 type Work @default.
• W2183688881 sameAs 2183688881 @default.
• W2183688881 citedByCount "0" @default.
• W2183688881 crossrefType "journal-article" @default.
• W2183688881 hasAuthorship W2183688881A5079477497 @default.
• W2183688881 hasConcept C126322002 @default.
• W2183688881 hasConcept C134018914 @default.
• W2183688881 hasConcept C185592680 @default.
• W2183688881 hasConcept C25642318 @default.
• W2183688881 hasConcept C2776999253 @default.
• W2183688881 hasConcept C2777180221 @default.
• W2183688881 hasConcept C2778854520 @default.
• W2183688881 hasConcept C2779306644 @default.
• W2183688881 hasConcept C2910068830 @default.
• W2183688881 hasConcept C55493867 @default.
• W2183688881 hasConcept C555293320 @default.
• W2183688881 hasConcept C71924100 @default.
• W2183688881 hasConceptScore W2183688881C126322002 @default.
• W2183688881 hasConceptScore W2183688881C134018914 @default.
• W2183688881 hasConceptScore W2183688881C185592680 @default.
• W2183688881 hasConceptScore W2183688881C25642318 @default.
• W2183688881 hasConceptScore W2183688881C2776999253 @default.
• W2183688881 hasConceptScore W2183688881C2777180221 @default.
• W2183688881 hasConceptScore W2183688881C2778854520 @default.
• W2183688881 hasConceptScore W2183688881C2779306644 @default.
• W2183688881 hasConceptScore W2183688881C2910068830 @default.
• W2183688881 hasConceptScore W2183688881C55493867 @default.
• W2183688881 hasConceptScore W2183688881C555293320 @default.
• W2183688881 hasConceptScore W2183688881C71924100 @default.
• W2183688881 hasLocation W21836888811 @default.
• W2183688881 hasOpenAccess W2183688881 @default.
• W2183688881 hasPrimaryLocation W21836888811 @default.
• W2183688881 isParatext "false" @default.
• W2183688881 isRetracted "false" @default.
• W2183688881 magId "2183688881" @default.
• W2183688881 workType "article" @default.